文献速递肝病消化道肿瘤与早癌

早期治疗中血清HBV RNA下降在预测慢性乙型肝炎患者肝细胞癌风险中的作用

Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-23

研究纳入2个前瞻性慢性乙型肝炎队列共1374例接受核苷(酸)类似物治疗的患者,检测基线及治疗第1、2、3年血清HBV RNA。中位随访5.4年,76例发生肝细胞癌。治疗第1年和第2年HBV RNA下降与肝细胞癌风险独立相关,将其纳入现有风险评分可提升预测性能。

要点

  • 治疗第1年HBV RNA下降(调整后HR 0.70,P=0.009)与肝细胞癌风险独立相关。
  • 治疗第2年HBV RNA下降(调整后HR 0.71,P=0.016)与肝细胞癌风险独立相关。
  • 第1年下降≤0.4 log10 copies/mL或第2年≤0.6 log10 copies/mL者肝细胞癌风险分别高2.22倍和2.09倍。

核心结论

  • 治疗第1年和第2年血清HBV RNA下降与治疗中肝细胞癌风险显著相关。
  • 将早期治疗中HBV RNA下降纳入肝细胞癌风险预测模型,可作为指导核苷(酸)类似物治疗患者适当监测策略的有用工具。

研究设计与样本

  • 从2个前瞻性慢性乙型肝炎队列纳入1374例接受核苷(酸)类似物治疗的患者。
  • 在基线及治疗第1、2、3年检测血清HBV RNA。
  • 采用Cox比例风险模型分析HBV RNA动力学与肝细胞癌风险的关联。

主要发现

  • 中位随访5.4年,76例患者发生肝细胞癌。
  • 治疗第1年HBV RNA下降与肝细胞癌风险独立相关(调整后HR 0.70,P=0.009)。
  • 治疗第2年HBV RNA下降与肝细胞癌风险独立相关(调整后HR 0.71,P=0.016)。
  • 第1年HBV RNA下降≤0.4 log10 copies/mL者肝细胞癌风险是下降较多者的2.22倍。
  • 第2年HBV RNA下降≤0.6 log10 copies/mL者肝细胞癌风险是下降较多者的2.09倍。

关键数值与推荐

  • 将第1年HBV RNA下降纳入PAGE-B评分后,C指数为0.814,而基于基线参数的PAGE-B评分为0.78。
  • 将早期治疗中HBV RNA下降纳入PAGE-B、mPAGE-B和aMAP评分可提升其预测性能。

临床怎么用

  • 作者认为,将早期治疗中HBV RNA下降纳入肝细胞癌风险预测模型可作为指导核苷(酸)类似物治疗患者适当监测策略的有用工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) risk prediction models established in patients with chronic hepatitis B receiving nucleos(t)ide analogue (NA) rarely include viral factors because of mediocre predictability of traditional viral markers. Here, we investigate the role of serum hepatitis B virus (HBV) RNA, a novel biomarker, in predicting HCC risk in NA-treated patients. METHODS: A total of 1374 NA-treated patients were enrolled from 2 prospective chronic hepatitis B cohorts. Serum HBV RNA was detected at baseline, year 1, 2 and 3 of treatment. Cox proportional-hazard model was used to investigate the association of HBV RNA kinetics with HCC risk. RESULTS: After a median follow-up of 5.4 years, 76 patients developed HCC. HBV RNA declines at year 1 (adjusted hazard ratio, 0.70; P = .009) and 2 (adjusted hazard ratio, 0.71; P = .016) were independently associated with HCC risk. Patients with less HBV RNA decline at year 1 (≤0.4 log10 copies/mL) or 2 (≤0.6 log10 copies/mL) had 2.22- and 2.09-folds higher HCC risk, respectively, than those with more declines. When incorporating these early on-treatment HBV RNA declines into existing HCC risk scores, including PAGE-B (age, sex, and platelets), modified PAGE-B (mPAGE-B) (age, sex, platelets, and albumin), and aMAP (age, sex, platelets, and albumin-bilirubin score) score, they could enhance their predictive performance (ie, C-index 0.814 vs 0.78 [model (PAGE-B + year-1 HBV RNA decline) vs PAGE-B score based on baseline parameters]). CONCLUSIONS: Serum HBV RNA declines at year 1 and 2 were significantly associated with on-treatment HCC risk. Incorporating early on-treatment HBV RNA declines into HCC risk prediction models can be useful tools to guide appropriate surveillance strategies in NA-treated patients.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Liu S, Wong GL, Fan R, et al. Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2024. PMID: 39181427. doi:10.1016/j.cgh.2024.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。